NeurologyLive® Friday 5 — January 23, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Click the read more buttons for more details and information about each highlight.

1: What the EC Decision on High-Dose Spinraza Means for SMA Care

In a recent Q&A, Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave her immediate reaction to the European Commission approval of high-dose nusinersen and its implications for evolving spinal muscular atrophy treatment strategies.

2: Advancing Alzheimer Diagnosis and Treatment Through Mechanism-Based Approaches: Takeshi Iwatsubo, MD, PhD

In an interview at CTAD 2025, Takeshi Iwatsubo, MD, PhD, director at the National Center of Neurology and Psychiatry, discussed how biomarker-driven diagnostics and antibody therapies targeting amyloid pathology may be reshaping Alzheimer disease management. [WATCH TIME: 4 minutes]

3: Shifting Alzheimer Detection Upstream Using Digital Cognitive Assessments: John Showalter, MD, MSIS

In an interview at CTAD 2025, John Showalter, MD, MSIS, chief operating officer at Linus Health, talked about how brief, digitally administered cognitive assessments enable scalable, earlier identification of cognitive impairment. [WATCH TIME: 4 minutes]

4: NeuroVoices: Sneha Mantri, MD, MS, on Addressing Depression and Anxiety in Parkinson Care

In our latest NeuroVoices Q&A, Sneha Mantri, MD, MS, chief medical officer at the Parkinson’s Foundation, detailed how mood and behavioral symptoms shape quality of life in Parkinson disease and how clinicians can better identify and manage them.

5: Enhancing Biomarker Use and Targeted Treatment Approaches in Alzheimer Disease: Aaron Burstein, PharmD

In an interview at CTAD 2025, Aaron Burstein, PharmD, head of search and evaluation at the Alzheimer's Drug Discovery Foundation, discussed the evolving role of biomarkers for diagnosis and the progress of targeted therapies in Alzheimer disease. [WATCH TIME: 5 minutes]

Click here to view more video interviews with neurology experts.